Scarica l'app Stockscreener
0.794
1.37%
-0.011
Dopo l'orario di chiusura:
.78
-0.014
-1.76%
Precedente Chiudi:
$0.805
Aprire:
$0.794
Volume 24 ore:
298.09K
Relative Volume:
0.31
Capitalizzazione di mercato:
$3.96M
Reddito:
-
Utile/perdita netta:
$-15.52M
Rapporto P/E:
-0.0427
EPS:
-18.58
Flusso di cassa netto:
$-16.61M
1 W Prestazione:
-7.61%
1M Prestazione:
-75.03%
6M Prestazione:
-86.22%
1 anno Prestazione:
-97.80%
Intervallo 1D:
$0.7803
$0.8106
Intervallo di 1 settimana:
$0.773
$0.8758
Portata 52W:
$0.773
$60.80
Revelation Biosciences Inc Stock (REVB) Company Profile
Nome
Revelation Biosciences Inc
Settore
Industria
Telefono
650-800-3717
Indirizzo
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Confronta REVB con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
0.794 | 3.96M | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.45 | 115.69B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
529.24 | 53.25B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
307.99 | 39.22B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.89 | 35.78B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
269.63 | 27.68B | 3.81B | -644.79M | -669.77M | -6.24 |
Revelation Biosciences Inc Borsa (REVB) Ultime notizie
Phase 2b Trial Data on Treatment for Inflammation Due Soon - streetwisereports.com
Equities Analysts Offer Predictions for REVB FY2028 Earnings - Defense World
Revelation Biosciences Raises $4M in Public Offering - TipRanks
REVBRevelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering - mx.advfn.com
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - mx.advfn.com
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - mx.advfn.com
Revelation Biosciences Inc (REVB) Shares Rise Despite Market Challenges - News Heater
REVB stock touches 52-week low at $0.86 amid sharp annual decline By Investing.com - Investing.com South Africa
Revelation Biosciences, Inc. (REVB) Raises $4M in Public Offering - Insider Monkey
Revelation Biosciences sets terms for $4 million public offering By Investing.com - Investing.com Canada
Revelation Biosciences, Inc. Announces Closing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering - Business Wire
REVB stock touches 52-week low at $0.86 amid sharp annual decline - Investing.com Canada
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering - BioSpace
Revelation Biosciences Announces Pricing Of $4 Million Public Offering - marketscreener.com
Revelation Biosciences sets terms for $4 million public offering - Investing.com Australia
Pre-market Movers: ALZN, HCTI, REVB, NTLA... - RTTNews
Revelation Biosciences announces pricing of $4M public offering - MSN
Revelation Biosciences Board Member Resigns Amid New Role - TipRanks
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Revelation Biosciences board member steps down amid new focus - Investing.com Australia
Revelation Biosciences board member steps down amid new focus By Investing.com - Investing.com Canada
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors - The Joplin Globe
REVB: New Market Potential and Quarterly Results - Research Tree
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025 - BioSpace
Revelation Biosciences (REVB) Projected to Post Earnings on Friday - Defense World
Allergic Rhinitis Pipeline 2025: MOA, ROA, FDA-Approved Drugs, - openPR.com
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - BioSpace
REVB: New Target Market Announced - Research Tree
Peripheral Blood Mononuclear Cells Market Size to Hit USD 774.41 Bn by 2034 - Precedence Research
Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey
Pre-market Movers: IBO, ALUR, GCTK, TELA... - RTTNews
Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World
Arbor Biotechnologies Announces $73.9 Million Series C Financing to Advance Novel Gene Editing Therapeutics - GlobeNewswire
REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com
REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga
Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks
Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire
What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World
REVB: 2025 Is the Year for Measurable Progress - Research Tree
Revelation Biosciences Inc. (REVB) reports earnings - Quartz
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ
Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa
Revelation Biosciences Inc Azioni (REVB) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.91%
1.17%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):